Dulaglutide Gets Defensive Amid GLP-1 Competition
A review paper attempts to justify dulaglutide's place in the GLP-1 market. The data tells a different story about efficacy hierarchies.
Published June 9, 2026·4 min read·Evidence: Peer Reviewed
What They Found
This appears to be a review attempting to defend dulaglutide's clinical position against newer, more potent GLP-1 receptor agonists like semaglutide and dual-agonist tirzepatide. The authors argue for dulaglutide's continued relevance in cardiometabolic treatment.
Why It Matters
The GLP-1 space has clear efficacy hierarchies that make defensive positioning difficult. Semaglutide consistently demonstrates superior weight loss compared to dulaglutide in head-to-head trials, with weekly semaglutide producing 10-15% body weight reduction versus dulaglutide's 3-5% in most studies. Tirzepatide, combining GLP-1 and GIP receptor agonism, pushes weight loss even higher to 15-22% in clinical trials.
The mechanism differences matter clinically. All three compounds activate GLP-1 receptors to slow gastric emptying and enhance satiety, but dulaglutide's shorter half-life and different receptor binding profile translate to measurably weaker metabolic effects. Cardiovascular outcomes data exists for all three, but the magnitude of benefit correlates with metabolic improvement—where dulaglutide consistently underperforms.
From a practical standpoint, dulaglutide's main remaining advantage is cost and insurance coverage patterns. But as biosimilars emerge and semaglutide/tirzepatide gain broader coverage, even this positioning erodes.
What I'd Watch For
This reads like pharmaceutical marketing disguised as clinical guidance. Without access to the full methodology, I'm skeptical of any analysis that doesn't acknowledge the clear efficacy gaps between these compounds. The real question isn't whether dulaglutide "has a role"—it's whether that role will survive market pressures and clinical reality.
Future studies need to focus on specific patient populations where dulaglutide might offer unique advantages beyond cost. The current data suggests few such populations exist.
Bottom Line
Dulaglutide is a less effective GLP-1 agonist trying to maintain market share through positioning rather than performance. The mechanisms and clinical data don't support equivalence claims. I wouldn't switch patients from more effective options to dulaglutide based on this type of analysis.